{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:43:56Z","timestamp":1785807836397,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jcf.2023.08.009","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T06:45:46Z","timestamp":1694241946000},"page":"208-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Chronic rhinosinusitis in the era of CFTR modulator therapy"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-384X","authenticated-orcid":false,"given":"Roy Gavin","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-7639","authenticated-orcid":false,"given":"Christopher","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7102-1712","authenticated-orcid":false,"given":"Paul","family":"McNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jcf.2023.08.009_bib0001","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1513\/AnnalsATS.201910-777OC","article-title":"Magnetic resonance imaging detects chronic rhinosinusitis in infants and preschool children with cystic fibrosis","volume":"17","author":"Sommerburg","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.jcf.2023.08.009_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267986","article-title":"Alterations in innate immune responses of patients with chronic rhinosinusitis related to cystic fibrosis","volume":"17","author":"Rezende","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2023.08.009_bib0003","article-title":"Patient Registry 2020 Annual Data Report [internet]","year":"2020","journal-title":"Cyst Fibros Found"},{"issue":"8","key":"10.1016\/j.jcf.2023.08.009_bib0004","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/lary.27019","article-title":"Correlations between cystic fibrosis genotype and sinus disease severity in chronic rhinosinusitis","volume":"128","author":"Abuzeid","year":"2018","journal-title":"Laryngoscope"},{"issue":"4","key":"10.1016\/j.jcf.2023.08.009_bib0005","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/alr.21675","article-title":"T2R38 genotype is correlated with sinonasal quality of life in homozygous \u0394F508 cystic fibrosis patients","volume":"6","author":"Adappa","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"10.1016\/j.jcf.2023.08.009_bib0006","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11882-012-0250-y","article-title":"Pathogenesis and management of nasal polyposis in cystic fibrosis","volume":"12","author":"Mainz","year":"2012","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"10.1016\/j.jcf.2023.08.009_bib0007","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1513\/AnnalsATS.202101-057OC","article-title":"Impact of cystic fibrosis transmembrane conductance regulator therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient-reported outcomes","volume":"19","author":"Beswick","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2023.08.009_bib0008","doi-asserted-by":"crossref","DOI":"10.1002\/alr.22974","article-title":"Cystic fibrosis foundation otolaryngology care multidisciplinary consensus recommendations","author":"Kimple","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"10.1016\/j.jcf.2023.08.009_bib0009","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/lary.27595","article-title":"Impact of high- versus low-risk genotype on sinonasal radiographic disease in cystic fibrosis","volume":"129","author":"Halderman","year":"2019","journal-title":"Laryngoscope"},{"issue":"4","key":"10.1016\/j.jcf.2023.08.009_bib0010","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jcf.2013.10.011","article-title":"Sinonasal manifestations of cystic fibrosis: a correlation between genotype and phenotype?","volume":"13","author":"Berkhout","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2023.08.009_bib0011","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2500\/ajr.2007.21.2905","article-title":"The delta F508 mutation in cystic fibrosis and impact on sinus development","volume":"21","author":"Woodworth","year":"2007","journal-title":"Am J Rhinol"},{"issue":"11","key":"10.1016\/j.jcf.2023.08.009_bib0012","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/alr.21412","article-title":"Comparison of radiographic and clinical characteristics of low-risk and high-risk cystic fibrosis genotypes","volume":"4","author":"Ferril","year":"2014","journal-title":"Int Forum Allergy Rhinol"},{"issue":"7","key":"10.1016\/j.jcf.2023.08.009_bib0013","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ijporl.2014.04.030","article-title":"Effect of the F508del genotype on outcomes of endoscopic sinus surgery in children with cystic fibrosis","volume":"78","author":"Do","year":"2014","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.jcf.2023.08.009_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.03.002","article-title":"Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis","author":"Stapleton","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2023.08.009_bib0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"Suppl S29","key":"10.1016\/j.jcf.2023.08.009_bib0016","first-page":"1","article-title":"European Position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"issue":"4","key":"10.1016\/j.jcf.2023.08.009_bib0017","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4193\/Rhino14.028","article-title":"Comprehensive quality of life outcomes for pediatric patients undergoing endoscopic sinus surgery","volume":"52","author":"Taylor","year":"2014","journal-title":"Rhinology"},{"issue":"8","key":"10.1016\/j.jcf.2023.08.009_bib0018","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ppul.21261","article-title":"Chemosensory function and food preferences of children with cystic fibrosis","volume":"45","author":"Laing","year":"2010","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"10.1016\/j.jcf.2023.08.009_bib0019","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/lary.28332","article-title":"Olfactory cleft and sinus opacification differentially impact olfaction in chronic rhinosinusitis","volume":"130","author":"Loftus","year":"2020","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.jcf.2023.08.009_bib0020","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1016\/j.jcf.2021.09.014","article-title":"Olfactory dysfunction in cystic fibrosis: impact of CFTR modulator therapy","volume":"21","author":"Beswick","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2023.08.009_bib0021","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/1945892419870450","article-title":"Cystic fibrosis: the sense of smell","volume":"34","author":"Di Lullo","year":"2020","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"10.1016\/j.jcf.2023.08.009_bib0022","article-title":"Medical interventions for chronic rhinosinusitis in cystic fibrosis","volume":"4","author":"Karanth","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"24","key":"10.1016\/j.jcf.2023.08.009_bib0023","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122695","article-title":"Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR","volume":"3","author":"Donaldson","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2023.08.009_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.642180","article-title":"Ivacaftor reduces inflammatory mediators in upper airway lining fluid from cystic fibrosis patients with a G551D mutation: serial non-invasive home-based collection of upper airway lining fluid","volume":"12","author":"Mainz","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jcf.2023.08.009_bib0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/coa.12310","article-title":"Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation","volume":"40","author":"Sheikh","year":"2015","journal-title":"Clin Otolaryngol"},{"issue":"3","key":"10.1016\/j.jcf.2023.08.009_bib0026","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/alr.22251","article-title":"Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients","volume":"9","author":"McCormick","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"issue":"7","key":"10.1016\/j.jcf.2023.08.009_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235638","article-title":"The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients","volume":"15","author":"Gostelie","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jcf.2023.08.009_bib0028","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.jcf.2019.11.008","article-title":"Positive clinical outcomes following ivacaftor treatment in a cystic fibrosis patient with the genotype 3272\u201326A>G\/Q493X","volume":"19","author":"Pallin","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2023.08.009_bib0029","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jcf.2018.04.004","article-title":"Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations","volume":"18","author":"Guimbellot","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2023.08.009_bib0030","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.otohns.2007.01.024","article-title":"The sino-nasal outcome test (SNOT): can we make it more clinically meaningful?","volume":"136","author":"Browne","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"10.1016\/j.jcf.2023.08.009_bib0031","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jcf.2013.05.006","article-title":"Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation","volume":"12","author":"Hebestreit","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2023.08.009_bib0032","article-title":"P66\u2005Patient-reported outcomes in patients with cystic fibrosis with homozygous for the Phe508del CFTR mutation on lumacaftor-ivacaftor treatment: results from an observational study","volume":"77","author":"Arooj","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2023.08.009_bib0033","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1016\/S1569-1993(22)01264-4","article-title":"574 Determining the minimal clinically important difference for the 22-question SinoNasal Outcome Test (SNOT-22) in people with cystic fibrosis","volume":"21","author":"Beswick","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.08.009_bib0034","article-title":"Longitudinal MRI detects onset and progression of chronic rhinosinusitis from infancy to school age in cystic fibrosis","author":"Wucherpfennig","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2023.08.009_bib0035","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","author":"Dimango","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.08.009_bib0036","article-title":"Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis","author":"Douglas","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jcf.2023.08.009_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.06.003","article-title":"Elexacaftor-Tezacaftor-Ivacaftor improve gastro-oesophageal reflux and sinonasal symptoms in advanced cystic fibrosis","author":"Shakir","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.08.009_bib0038","article-title":"Improvement in sinonasal quality-of-life indicators for pediatric patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor","author":"Castellanos","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jcf.2023.08.009_bib0039","doi-asserted-by":"crossref","first-page":"S317","DOI":"10.1016\/S1569-1993(22)01261-9","article-title":"571 Impact of HEMT on chronic rhinosinusitis: 2-year follow-up with machine learning computed tomography analysis and patient-reported outcomes","volume":"21","author":"Beswick","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.08.009_bib0040","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/S1569-1993(22)00375-7","article-title":"P042 The effect of elexacaftor\/tezacaftor\/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis","volume":"21","author":"Allgood","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.08.009_bib0041","doi-asserted-by":"crossref","DOI":"10.1007\/s00405-023-07859-4","article-title":"Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis","author":"Bode","year":"2023","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"6","key":"10.1016\/j.jcf.2023.08.009_bib0042","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.chembiol.2022.02.001","article-title":"A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease","volume":"29","author":"Douglas","year":"2022","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.jcf.2023.08.009_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.03.011","article-title":"Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis","author":"Wucherpfennig","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2023.08.009_bib0044","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5334\/jbsr.2812","article-title":"Sinus disease grading on computed tomography before and after modulating therapy in adult patients with cystic fibrosis","volume":"106","author":"Tagliati","year":"2022","journal-title":"J Belg Soc Radiol"},{"key":"10.1016\/j.jcf.2023.08.009_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2022.110421","article-title":"Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: early report","volume":"154","author":"Bec","year":"2022","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jcf.2023.08.009_bib0046","article-title":"Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis","author":"Wucherpfennig","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2023.08.009_bib0047","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/alr.22891","article-title":"Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort","volume":"12","author":"Bacon","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"issue":"14","key":"10.1016\/j.jcf.2023.08.009_bib0048","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.284.14.1814","article-title":"Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population","volume":"284","author":"Wang","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2023.08.009_bib0049","unstructured":"Woodworth B. Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis 2018 [updated June 2021; cited 2022 27th March]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03439865?term=ivacaftor&draw=3&rank=11."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323008779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323008779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T08:23:54Z","timestamp":1772353434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323008779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1569199323008779"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.08.009","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic rhinosinusitis in the era of CFTR modulator therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}